Cargando…

External Validation of Adjuvant! Online Breast Cancer Prognosis Tool. Prioritising Recommendations for Improvement

BACKGROUND: Adjuvant! Online is a web-based application designed to provide 10 years survival probability of patients with breast cancer. Several predictors have not been assessed in the original Adjuvant! Online study. We provide the validation of Adjuvant! Online algorithm on two breast cancer dat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hajage, David, de Rycke, Yann, Bollet, Marc, Savignoni, Alexia, Caly, Martial, Pierga, Jean-Yves, Horlings, Hugo M., Van de Vijver, Marc J., Vincent-Salomon, Anne, Sigal-Zafrani, Brigitte, Senechal, Claire, Asselain, Bernard, Sastre, Xavier, Reyal, Fabien
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2011
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3210791/ https://www.ncbi.nlm.nih.gov/pubmed/22087319 http://dx.doi.org/10.1371/journal.pone.0027446

Ejemplares similares

Long-Term Prognostic Performance of Ki67 Rate in Early Stage, pT1-pT2, pN0, Invasive Breast Carcinoma
por: Reyal, Fabien, et al.
Publicado: (2013)

Respective Prognostic Value of Genomic Grade and Histological Proliferation Markers in Early Stage (pN0) Breast Carcinoma
por: Reyal, Fabien, et al.
Publicado: (2012)

Correction: Respective Prognostic Value of Genomic Grade and Histological Proliferation Markers in Early Stage (pN0) Breast Carcinoma
por: Reyal, Fabien, et al.
Publicado: (2012)

The Molecular Subtype Classification Is a Determinant of Sentinel Node Positivity in Early Breast Carcinoma
por: Reyal, Fabien, et al.
Publicado: (2011)

Are ipsilateral breast tumour invasive recurrences in young (⩽40 years) women more aggressive than their primary tumours?
por: Sigal-Zafrani, B, et al.
Publicado: (2007)

Non-Sentinel Lymph Node Metastasis Prediction in Breast Cancer with Metastatic Sentinel Lymph Node: Impact of Molecular Subtypes Classification
por: Reyal, Fabien, et al.
Publicado: (2012)

Epigenomic Alterations in Breast Carcinoma from Primary Tumor to Locoregional Recurrences
por: Moarii, Matahi, et al.
Publicado: (2014)

High rates of breast conservation for large ductal and lobular invasive carcinomas combining multimodality strategies
por: Bollet, M A, et al.
Publicado: (2008)

Tumor aromatase expression as a prognostic factor for local control in young breast cancer patients after breast-conserving treatment
por: Bollet, Marc A, et al.
Publicado: (2009)

Histological grade concordance between diagnostic core biopsy and corresponding surgical specimen in HR-positive/HER2-negative breast carcinoma
por: Daveau, C, et al.
Publicado: (2014)

Matching methods to create paired survival data based on an exposure occurring over time: a simulation study with application to breast cancer
por: Savignoni, Alexia, et al.
Publicado: (2014)

Time-varying effect and long-term survival analysis in breast cancer patients treated with neoadjuvant chemotherapy
por: Baulies, S, et al.
Publicado: (2015)

Estrogen-Receptor, Progesterone-Receptor and HER2 Status Determination in Invasive Breast Cancer. Concordance between Immuno-Histochemistry and MapQuant™ Microarray Based Assay
por: Mouttet, D., et al.
Publicado: (2016)

Impact of Adjuvant Chemotherapy on Breast Cancer Survival: A Real-World Population
por: Rossi, Lea, et al.
Publicado: (2015)

Heterochromatin protein 1α: a hallmark of cell proliferation relevant to clinical oncology
por: De Koning, Leanne, et al.
Publicado: (2009)

Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant Chemotherapy
por: Bonsang-Kitzis, Hélène, et al.
Publicado: (2015)

Pooling breast cancer datasets has a synergetic effect on classification performance and improves signature stability
por: van Vliet, Martin H, et al.
Publicado: (2008)

Pathological complete response and prognosis after neoadjuvant chemotherapy for HER2-positive breast cancers before and after trastuzumab era: results from a real-life cohort
por: Hamy, Anne-Sophie, et al.
Publicado: (2018)

Enrichment methods to detect bone marrow micrometastases in breast carcinoma patients: clinical relevance
por: Choesmel, Valérie, et al.
Publicado: (2004)

Pathological complete response and prognosis after neoadjuvant chemotherapy for HER2-positive breast cancers before and after trastuzumab era: results from a real-life cohort
por: Hamy-Petit, Anne-Sophie, et al.
Publicado: (2016)

Medico-economic impact of MSKCC non-sentinel node prediction nomogram for ER-positive HER2-negative breast cancers
por: Bonsang-Kitzis, Hélène, et al.
Publicado: (2017)

Reasons of not having breast reconstruction: a historical cohort of 1937 breast cancer patients undergoing mastectomy
por: Héquet, Delphine, et al.
Publicado: (2013)

Correction: Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant Chemotherapy
por: Bonsang-Kitzis, Hélène, et al.
Publicado: (2016)

Second malignancies after breast cancer: the impact of different treatment modalities
por: Kirova, Y M, et al.
Publicado: (2008)

Bilateral Poly Implant Prothèse Implant Rupture: An Uncommon Presentation
por: Mallon, Peter, et al.
Publicado: (2013)

On the use of propensity scores in case of rare exposure
por: Hajage, David, et al.
Publicado: (2016)

HER2 status of bone marrow micrometastasis and their corresponding primary tumours in a pilot study of 27 cases: a possible tool for anti-HER2 therapy management?
por: Vincent-Salomon, A, et al.
Publicado: (2007)

Cdk4/6 inhibitors and overall survival: power of first-line trials in metastatic breast cancer
por: Tanguy, Marie-Laure, et al.
Publicado: (2018)

Genomic Instability: A Stronger Prognostic Marker Than Proliferation for Early Stage Luminal Breast Carcinomas
por: Vincent-Salomon, Anne, et al.
Publicado: (2013)

Importance of pre-analytical steps for transcriptome and RT-qPCR analyses in the context of the phase II randomised multicentre trial REMAGUS02 of neoadjuvant chemotherapy in breast cancer patients
por: de Cremoux, Patricia, et al.
Publicado: (2011)

Adjuvant chemotherapy for breast cancer after preoperative chemotherapy: A propensity score matched analysis
por: Labrosse, Julie, et al.
Publicado: (2020)

8p22 MTUS1 Gene Product ATIP3 Is a Novel Anti-Mitotic Protein Underexpressed in Invasive Breast Carcinoma of Poor Prognosis
por: Rodrigues-Ferreira, Sylvie, et al.
Publicado: (2009)

Identification of typical medullary breast carcinoma as a genomic sub-group of basal-like carcinomas, a heterogeneous new molecular entity
por: Vincent-Salomon, Anne, et al.
Publicado: (2007)

A comprehensive analysis of prognostic signatures reveals the high predictive capacity of the Proliferation, Immune response and RNA splicing modules in breast cancer
por: Reyal, Fabien, et al.
Publicado: (2008)

Prioritising business processes: design and evaluation of the prioritisation and categorisation method (PCM)
por: Ohlsson, Jens, et al.
Publicado: (2017)

Functional characterization of the 19q12 amplicon in grade III breast cancers
por: Natrajan, Rachael, et al.
Publicado: (2012)

Prioritising quality improvement
por: Bircher, Joanna
Publicado: (2019)

Determinants of return at work of breast cancer patients: results from the OPTISOINS01 French prospective study
por: Arfi, Alexandra, et al.
Publicado: (2018)

Treatments During Pregnancy Targeting ERBB2 and Outcomes of Pregnant Individuals and Newborns
por: Gougis, Paul, et al.
Publicado: (2023)

Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas
por: Kreike, Bas, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_io93rmif0u5kbauc4ebtkl395u